Lindbrook Capital’s Tarsus Pharmaceuticals TARS Stock Holding History

Lindbrook Capital’s Portfolio TARS Stock Details TARS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	$6.01K	Buy	117 +7	+6%	+$346	﹤0.01%	1880
2024 Q4	$6.09K	Hold	110	–	–	﹤0.01%	1897
2024 Q3	$3.62K	Sell	110 -9	-8%	-$253	﹤0.01%	2141
2024 Q2	$3.23K	Buy	119 +25	+27%	+$841	﹤0.01%	2188
2024 Q1	$3.42K	Hold	94	–	–	﹤0.01%	2057
2023 Q4	$1.9K	Hold	94	–	–	﹤0.01%	2279
2023 Q3	$1.67K	Hold	94	–	–	﹤0.01%	2182
2023 Q2	$1.7K	Buy	+94	New	+$1.49K	﹤0.01%	2212
2022 Q4	–	Sell	-106	Closed	-$2K	–	3004
2022 Q3	$2K	Sell	106 -11	-9%	-$175	﹤0.01%	2149
2022 Q2	$2K	Buy	+117	New	+$1.76K	﹤0.01%	2056

Other funds holding TARS

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Lindbrook Capital's TARS Position: Q1 2025 in Review

Lindbrook Capital increased its Tarsus Pharmaceuticals (TARS) stake by 6.4% in Q1 2025, buying an estimated $346 and bringing the position to 117 shares worth $6.01K. The position accounts for ﹤0.01% of the portfolio, ranked #1880.

Lindbrook Capital first reported a position in TARS in Q2 2022 and has held it in 10 quarters since. The position peaked at $6.09K in Q4 2024. 194 funds tracked by Wall St. Rank hold TARS as of Q1 2025.

Lindbrook Capital held 117 shares of Tarsus Pharmaceuticals worth $6.01K as of Q1 2025.
Lindbrook Capital bought 7 Tarsus Pharmaceuticals shares in Q1 2025, an estimated $346.
Tarsus Pharmaceuticals made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #1880 holding.
Lindbrook Capital first reported a position in Tarsus Pharmaceuticals in Q2 2022 and has held it in 10 quarters since.
Lindbrook Capital's Tarsus Pharmaceuticals position peaked at $6.09K in Q4 2024.
194 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.